MapLight Therapeutics, Inc. (MPLT)
NASDAQ:MPLT
Want to see MPLT full AI Analyst Report?
MPLT Stock Chart & Stats
$17.49
--
Market closed
$17.49
--
Day’s Range― - ―
52-Week Range$12.24 - $33.28
Previous CloseN/A
VolumeN/A
Average Volume (3M)401.63K
Market Cap
$1.29B
Enterprise Value-$17.02M
Total Cash (Recent Filing)$305.10M
Total Debt (Recent Filing)$5.80M
Price to Earnings (P/E)―
Beta2.02
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding42,436,325
10 Day Avg. Volume205,334
30 Day Avg. Volume401,626
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)1.69
Price to Sales (P/S)0.00
P/FCF Ratio-5.58
Enterprise Value/Market Cap-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit29.44
Enterprise Value/Ebitda0.10
Forecast
1Y Price Target
$36.00Price Target Upside105.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-4.04
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthVery low financial leverage and sizable equity (~$458M) provide durable flexibility to fund multi-year clinical programs. This reduces near-term refinancing pressure, supports disciplined R&D spending, and preserves strategic optionality while the pipeline progresses toward value-driving milestones.
Cash RunwayA cash balance of ~$453M and an asserted runway into 2027 give the company time to complete key Phase 2 programs and readouts without immediate capital raises. That runway materially lowers near-term dilution risk and allows focus on clinical execution to derisk programs before seeking new funding.
CNS Pipeline Depth And Regulatory ProgressMultiple CNS programs across schizophrenia, Alzheimer’s psychosis, autism and next-generation M1/M4 diversify clinical risk and create multiple value pathways. FDA Fast Track for ML-007C-MA indicates regulatory engagement that can accelerate development and enhance the probability of a timely, value-accretive outcome.
Bears Say
Pre-revenue With Widening LossesThe company remains pre-revenue while operating losses more than doubled in 2025, reflecting a rising cost base without offsetting income. Over the medium term, persistent widening losses increase dependence on external capital and elevate execution risk before any commercial revenue can support operations.
Accelerating Cash BurnOperating cash flow and free cash flow worsened materially year-over-year, showing a cash-based ramp in spending tied to R&D and operations. Sustained acceleration in cash burn shortens actual runway, increases the probability of dilutive financings, and could force reprioritization of programs absent revenue or cost reductions.
Financing And Dilution RiskGiven the pre-revenue model and rising cash consumption, the company must access external capital to complete its pipeline; the FinancialSummary explicitly notes elevated funding risk. Dependence on new financing can dilute shareholders, constrain strategic choices, and pressure execution timing if market conditions deteriorate.
MapLight Therapeutics, Inc. News
MPLT FAQ
What was MapLight Therapeutics, Inc.’s price range in the past 12 months?
MapLight Therapeutics, Inc. lowest stock price was $12.24 and its highest was $33.28 in the past 12 months.
What is MapLight Therapeutics, Inc.’s market cap?
MapLight Therapeutics, Inc.’s market cap is $1.29B.
When is MapLight Therapeutics, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were MapLight Therapeutics, Inc.’s earnings last quarter?
Currently, no data Available
Is MapLight Therapeutics, Inc. overvalued?
According to Wall Street analysts MapLight Therapeutics, Inc.’s price is currently Undervalued.
Does MapLight Therapeutics, Inc. pay dividends?
MapLight Therapeutics, Inc. does not currently pay dividends.
What is MapLight Therapeutics, Inc.’s EPS estimate?
MapLight Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does MapLight Therapeutics, Inc. have?
MapLight Therapeutics, Inc. has 42,436,325 shares outstanding.
What happened to MapLight Therapeutics, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of MapLight Therapeutics, Inc.?
Currently, no hedge funds are holding shares in MPLT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MapLight Therapeutics, Inc. Stock Smart Score
Company Description
MapLight Therapeutics, Inc.
MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer's disease psychosis; ML-004 for the treatment of social communication deficit and/or irritability in autism spectrum disorder; ML-021 for the treatment of motor deficits in Parkinson's disease; and ML-009, a G-protein-coupled receptor 52 positive allosteric modulator for the treatment of hyperactivity, impulsivity and agitation-related disorders. The company also develops platform identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation. MapLight Therapeutics, Inc. was formerly known as Alvarado Therapeutics, Inc. and changed its name to MapLight Therapeutics, Inc. in August 2019. MapLight Therapeutics, Inc. was incorporated in 2018 and is based in Redwood City, California. MapLight Therapeutics, Inc operates as a subsidiary of Catalyst4, Inc.
MPLT Stock 12 Month Forecast
Average Price Target
$36.00
▲(105.83% Upside)
Scinai Immunotherapeutics
―
Sensei Biotherapeutics
―
GRI Bio
―
Dermata Therapeutics
―
Azitra Inc
―
Ownership Overview
64.15% Insiders
6.26% Mutual Funds
0.03% Other Institutional Investors
25.50% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---